Maven Capital Partners exits investment in Blacktrace Group

• Carlyle-backed Unchained Labs is the buyer
• Maven invested in Blacktrace in 2016
• Maven is an alternative asset manager based in Glasgow, Scotland

Maven Capital Partners has exited its investment in Blacktrace Group, a developer and supplier of scientific instrumentation and products, to Carlyle-backed Unchained Labs.

Blacktrace is based in Hertfordshire, England.

Maven invested in Blacktrace in 2016.

“The team’s ability to constantly innovate and create novel, high value life science products is remarkable, and Unchained is acquiring a recognised name in applications as varied as microfluidics, vaccines, gene therapy and single-cell genomics analysis,” said David Milroy, partner at Maven.

Blacktrace is Maven’s third profitable exit in 2023, according to a release.

Carlyle acquired Unchained Labs in 2021.

Unchained Labs is a life sciences tools company focused on solving problems for biologics and gene therapy researchers. The company is based in Pleasanton, California.

Carlyle is a global investment firm headquartered in Washington DC.

Maven is an alternative asset manager based in Glasgow, Scotland.